Respiratory Diseases of Adults

[1]  J. Scott,et al.  Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya , 2000, The Lancet.

[2]  A. García de Lorenzo,et al.  Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis , 1999, Intensive Care Medicine.

[3]  G. Raghu,et al.  The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. , 1995, Chest.

[4]  P. O'Malley,et al.  Should Health-Care Systems Pay for Replacement Therapy in Patients With α1-Antitrypsin Deficiency? , 2000 .

[5]  A. Aaviksoo,et al.  Costs of asthma treatment in Estonia. , 2001, European journal of public health.

[6]  S. Sullivan,et al.  The health economics of asthma and rhinitis. I. Assessing the economic impact. , 2001, The Journal of allergy and clinical immunology.

[7]  R. Stelmach,et al.  Evaluation of health-related quality of life in low-income patients with COPD receiving long-term oxygen therapy. , 2003, Chest.

[8]  M. Raviglione,et al.  Global tuberculosis incidence and mortality during 1990-2000. , 1994, Bulletin of the World Health Organization.

[9]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[10]  J. LaDou.  The asbestos cancer epidemic. , 2003, Environmental health perspectives.

[11]  T. Clemmer,et al.  Prolonged mechanical ventilation for respiratory failure: A cost‐benefit analysis , 1983, Critical care medicine.

[12]  E. Manor,et al.  Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. , 1996, Thorax.

[13]  S. Stearns,et al.  Reductions in hospital use from self management training for chronic asthmatics. , 1998, Social science & medicine.

[14]  E. Doorslaer,et al.  Economic appraisal of asthma and COPD care: a literature review 1980-1991. , 1992, Social science & medicine.

[15]  K. Weiss,et al.  An update on the health economics of asthma and allergy , 2002, Current opinion in allergy and clinical immunology.

[16]  A. Ng,et al.  A study on community acquired pneumonia in adults requiring hospital admission in Penang. , 2001, The Medical journal of Malaysia.

[17]  P A West,et al.  Economic evaluation of strategies for the control and management of influenza in Europe. , 2002, Vaccine.

[18]  W C Tan,et al.  Prospective study of the aetiology of adult community acquired bacterial pneumonia needing hospitalisation in Singapore. , 1993, Singapore medical journal.

[19]  J. Hay,et al.  Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. , 1991, American journal of public health.

[20]  R. Loewenson.  Assessment of the health impact of occupational risk in Africa: current situation and methodological issues. , 1999, Epidemiology.

[21]  Barrett T. Kitch,et al.  Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. , 2001, The Journal of allergy and clinical immunology.

[22]  D. Dockery,et al.  Chronic obstructive pulmonary disease mortality in six U.S. cities. , 1989, The American review of respiratory disease.

[23]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[24]  J Bousquet,et al.  Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. , 2001, Bulletin of the World Health Organization.

[25]  B. Williams,et al.  Occupational lung disease in ex-mineworkers--sound a further alarm! , 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[26]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[27]  C. van Weel,et al.  The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program. , 2001, American journal of respiratory and critical care medicine.

[28]  A. Crockett,et al.  A review of long-term oxygen therapy for chronic obstructive pulmonary disease. , 2001, Respiratory medicine.

[29]  T. Perneger,et al.  Objectives, methods and content of patient education programmes for adults with asthma: systematic review of studies published between 1979 and 1998 , 1999, Thorax.

[30]  Joel Huber,et al.  Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults , 2002, Annals of Internal Medicine.

[31]  M. Koopmanschap,et al.  Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. , 1998, Chest.

[32]  D. Low,et al.  SARS--one year later. , 2003, The New England journal of medicine.

[33]  A. Hedley,et al.  Cost-effectiveness study on influenza prevention in Hong Kong. , 2001, Health policy.

[34]  K. R. Smith.  National burden of disease in India from indoor air pollution. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Jefferson,et al.  Prevention and early treatment of influenza in healthy adults. , 2000, Vaccine.

[36]  R. Kaplan,et al.  The Costs and Effects of Behavioral Programs in Chronic Obstructive Pulmonary Disease , 1984, Medical care.

[37]  F. Chew,et al.  The economic cost of asthma in Singapore. , 1999, Australian and New Zealand journal of medicine.

[38]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[39]  C. Fletcher.  The Natural history of chronic bronchitis and emphysema: An eight-year study of early chronic obstructive lung disease in working men in London , 1976 .

[40]  S. Sullivan,et al.  Health economics of asthma and rhinitis. II. Assessing the value of interventions. , 2001, The Journal of allergy and clinical immunology.

[41]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[42]  P. Dorinsky,et al.  Combination Therapy with Inhaled Long‐Acting β2‐Agonists and Inhaled Corticosteroids: A Paradigm Shift in Asthma Management , 2002, Pharmacotherapy.

[43]  A. Morice,et al.  Assessing the burden of respiratory disease in the UK. , 2002, Respiratory medicine.

[44]  P Macaskill,et al.  Global burden of disease and injury due to occupational factors. , 1999, Epidemiology.